Autophagy Activator Drugs: A New Opportunity in Neuroprotection from Misfolded Protein Toxicity

Stefano Thellung, Alessandro Corsaro, Mario Nizzari, Federica Barbieri, Tullio Florio

Research output: Contribution to journalReview article

9 Citations (Scopus)

Abstract

The aim of this review is to critically analyze promises and limitations of pharmacological inducers of autophagy against protein misfolding-associated neurodegeneration. Effective therapies against neurodegenerative disorders can be developed by regulating the "self-defense" equipment of neurons, such as autophagy. Through the degradation and recycling of the intracellular content, autophagy promotes neuron survival in conditions of trophic factor deprivation, oxidative stress, mitochondrial and lysosomal damage, or accumulation of misfolded proteins. Autophagy involves the activation of self-digestive pathways, which is different for dynamics (macro, micro and chaperone-mediated autophagy), or degraded material (mitophagy, lysophagy, aggrephagy). All neurodegenerative disorders share common pathogenic mechanisms, including the impairment of autophagic flux, which causes the inability to remove the neurotoxic oligomers of misfolded proteins. Pharmacological activation of autophagy is typically achieved by blocking the kinase activity of mammalian target of rapamycin (mTOR) enzymatic complex 1 (mTORC1), removing its autophagy suppressor activity observed under physiological conditions; acting in this way, rapamycin provided the first proof of principle that pharmacological autophagy enhancement can induce neuroprotection through the facilitation of oligomers' clearance. The demand for effective disease-modifying strategies against neurodegenerative disorders is currently stimulating the development of a wide number of novel molecules, as well as the re-evaluation of old drugs for their pro-autophagic potential.

Original languageEnglish
JournalInternational Journal of Molecular Sciences
Volume20
Issue number4
DOIs
Publication statusPublished - Feb 19 2019

Fingerprint

Autophagy
toxicity
Toxicity
drugs
disorders
Sirolimus
proteins
Proteins
neurons
oligomers
Oligomers
Neurons
Chemical activation
activation
Pharmaceutical Preparations
deprivation
suppressors
Oxidative stress
impairment
clearances

Keywords

  • autophagy
  • mTOR
  • neurodegenerative diseases
  • protein misfolding
  • rapamycin

ASJC Scopus subject areas

  • Catalysis
  • Molecular Biology
  • Spectroscopy
  • Computer Science Applications
  • Physical and Theoretical Chemistry
  • Organic Chemistry
  • Inorganic Chemistry

Cite this

Autophagy Activator Drugs : A New Opportunity in Neuroprotection from Misfolded Protein Toxicity. / Thellung, Stefano; Corsaro, Alessandro; Nizzari, Mario; Barbieri, Federica; Florio, Tullio.

In: International Journal of Molecular Sciences, Vol. 20, No. 4, 19.02.2019.

Research output: Contribution to journalReview article

Thellung, Stefano ; Corsaro, Alessandro ; Nizzari, Mario ; Barbieri, Federica ; Florio, Tullio. / Autophagy Activator Drugs : A New Opportunity in Neuroprotection from Misfolded Protein Toxicity. In: International Journal of Molecular Sciences. 2019 ; Vol. 20, No. 4.
@article{fc92a04e94244a2b99fcb54437c94d58,
title = "Autophagy Activator Drugs: A New Opportunity in Neuroprotection from Misfolded Protein Toxicity",
abstract = "The aim of this review is to critically analyze promises and limitations of pharmacological inducers of autophagy against protein misfolding-associated neurodegeneration. Effective therapies against neurodegenerative disorders can be developed by regulating the {"}self-defense{"} equipment of neurons, such as autophagy. Through the degradation and recycling of the intracellular content, autophagy promotes neuron survival in conditions of trophic factor deprivation, oxidative stress, mitochondrial and lysosomal damage, or accumulation of misfolded proteins. Autophagy involves the activation of self-digestive pathways, which is different for dynamics (macro, micro and chaperone-mediated autophagy), or degraded material (mitophagy, lysophagy, aggrephagy). All neurodegenerative disorders share common pathogenic mechanisms, including the impairment of autophagic flux, which causes the inability to remove the neurotoxic oligomers of misfolded proteins. Pharmacological activation of autophagy is typically achieved by blocking the kinase activity of mammalian target of rapamycin (mTOR) enzymatic complex 1 (mTORC1), removing its autophagy suppressor activity observed under physiological conditions; acting in this way, rapamycin provided the first proof of principle that pharmacological autophagy enhancement can induce neuroprotection through the facilitation of oligomers' clearance. The demand for effective disease-modifying strategies against neurodegenerative disorders is currently stimulating the development of a wide number of novel molecules, as well as the re-evaluation of old drugs for their pro-autophagic potential.",
keywords = "autophagy, mTOR, neurodegenerative diseases, protein misfolding, rapamycin",
author = "Stefano Thellung and Alessandro Corsaro and Mario Nizzari and Federica Barbieri and Tullio Florio",
year = "2019",
month = "2",
day = "19",
doi = "10.3390/ijms20040901",
language = "English",
volume = "20",
journal = "International Journal of Molecular Sciences",
issn = "1661-6596",
publisher = "MDPI AG",
number = "4",

}

TY - JOUR

T1 - Autophagy Activator Drugs

T2 - A New Opportunity in Neuroprotection from Misfolded Protein Toxicity

AU - Thellung, Stefano

AU - Corsaro, Alessandro

AU - Nizzari, Mario

AU - Barbieri, Federica

AU - Florio, Tullio

PY - 2019/2/19

Y1 - 2019/2/19

N2 - The aim of this review is to critically analyze promises and limitations of pharmacological inducers of autophagy against protein misfolding-associated neurodegeneration. Effective therapies against neurodegenerative disorders can be developed by regulating the "self-defense" equipment of neurons, such as autophagy. Through the degradation and recycling of the intracellular content, autophagy promotes neuron survival in conditions of trophic factor deprivation, oxidative stress, mitochondrial and lysosomal damage, or accumulation of misfolded proteins. Autophagy involves the activation of self-digestive pathways, which is different for dynamics (macro, micro and chaperone-mediated autophagy), or degraded material (mitophagy, lysophagy, aggrephagy). All neurodegenerative disorders share common pathogenic mechanisms, including the impairment of autophagic flux, which causes the inability to remove the neurotoxic oligomers of misfolded proteins. Pharmacological activation of autophagy is typically achieved by blocking the kinase activity of mammalian target of rapamycin (mTOR) enzymatic complex 1 (mTORC1), removing its autophagy suppressor activity observed under physiological conditions; acting in this way, rapamycin provided the first proof of principle that pharmacological autophagy enhancement can induce neuroprotection through the facilitation of oligomers' clearance. The demand for effective disease-modifying strategies against neurodegenerative disorders is currently stimulating the development of a wide number of novel molecules, as well as the re-evaluation of old drugs for their pro-autophagic potential.

AB - The aim of this review is to critically analyze promises and limitations of pharmacological inducers of autophagy against protein misfolding-associated neurodegeneration. Effective therapies against neurodegenerative disorders can be developed by regulating the "self-defense" equipment of neurons, such as autophagy. Through the degradation and recycling of the intracellular content, autophagy promotes neuron survival in conditions of trophic factor deprivation, oxidative stress, mitochondrial and lysosomal damage, or accumulation of misfolded proteins. Autophagy involves the activation of self-digestive pathways, which is different for dynamics (macro, micro and chaperone-mediated autophagy), or degraded material (mitophagy, lysophagy, aggrephagy). All neurodegenerative disorders share common pathogenic mechanisms, including the impairment of autophagic flux, which causes the inability to remove the neurotoxic oligomers of misfolded proteins. Pharmacological activation of autophagy is typically achieved by blocking the kinase activity of mammalian target of rapamycin (mTOR) enzymatic complex 1 (mTORC1), removing its autophagy suppressor activity observed under physiological conditions; acting in this way, rapamycin provided the first proof of principle that pharmacological autophagy enhancement can induce neuroprotection through the facilitation of oligomers' clearance. The demand for effective disease-modifying strategies against neurodegenerative disorders is currently stimulating the development of a wide number of novel molecules, as well as the re-evaluation of old drugs for their pro-autophagic potential.

KW - autophagy

KW - mTOR

KW - neurodegenerative diseases

KW - protein misfolding

KW - rapamycin

UR - http://www.scopus.com/inward/record.url?scp=85061964242&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061964242&partnerID=8YFLogxK

U2 - 10.3390/ijms20040901

DO - 10.3390/ijms20040901

M3 - Review article

C2 - 30791416

AN - SCOPUS:85061964242

VL - 20

JO - International Journal of Molecular Sciences

JF - International Journal of Molecular Sciences

SN - 1661-6596

IS - 4

ER -